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ABSTRACT 
 
Noha Shalaby, The American University in Cairo 
Advisor: Dr. Khalil ElKhodary, The American University in Cairo 
Co-advisor: Dr. Nejib Zemzemi, Carmen Group, INRIA, France 
 
Computational Modeling of Nanodrug-induced effect on Cardiac Electromechanics 
 
This work generally aims to promote the use of computational models for predicting 
side effects of nanodrugs under development, as a means to speed up the cycle of drug 
development, with potential savings on testing, and reduction in the need for animal 
or human testing.  
The specific objective of this thesis has been to accurately model a single ventricular 
contraction-relaxation cycle, and monitor the effects induced by nanodrugs on the 
electro-mechano-physiology of the left and right ventricles.  
Nanodrug interaction with ion channels located on cardiac cell membranes, such as 
those for sodium, potassium and calcium, can distort an electrical wave propagating 
through the tissue and can affect cardiac macroscale functions. In this study, a 
material model after Holzapfel and Ogden was developed to account for the 
anisotropic hyperelastic behavior of cardiac tissue, which was implemented on the 
open source software library Chaste. A coupled drug-electro-mechano-physiological 
system was then set up, also on Chaste, where a nanodrug effect was introduced into 
the cellular structure (nanoscale) as an ion channel inhibitor, and its influence then 
solved for, with respect to resulting electro-mechanical ventricular behaviors. Using 
quantifiable biomarkers, these effects were compared to the literature and clinical 
data. 
In this work we identified the following main results. Nanodrugs causing sodium 
channel blockage were found to produce the anticipated delays in electro-mechanics. 
Our study further predicted additional effects on LV twisting and LV & RV strain. On 
the other hand, nanodrugs causing potassium and calcium channel blockage revealed 
that cardiac mechanics is less responsive to mild alterations in electrophysiology, than 
electrophysiology is to ionic changes. Nonetheless, it is important to quantify these 
changes, as even a very small deviation from normal could accumulate over multiple 
cardiac cycles, and lead to adverse consequences on cardiac health in the long term. 
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1) Introduction 
 The objective of this study is to model a single ventricular contraction-  
relaxation cycle and monitor the nanodrug-induced effect on their electro-mechano-
physiology. The introduction is divided into subsections. First, the structure and 
function of the heart will be briefly stated to clarify the terminology that will be used 
throughout the thesis. Next, nanomedicine is introduced and how its use can affect the 
heart's functionality. After that, the motivation for testing nanoparticles for 
cardiotoxicity is justified by pointing to a number of studies that have thus far shown 
how certain nanoparticles under investigation for nanomedical research can cause 
unwanted biological interactions. The following section goes through how 
cardiotoxicity is quantified. Following that is a review of how research has been 
gauging the risk of drugs being cardiotoxic and the evolution into computational 
models for predicitive assessment. Next, the objectives of this thesis are stated in 
more detail and the software package chosen to build the problem is presented. 
Finally, there is a quick run through the organization of the thesis sections. 
A) The Structure and Function of the Heart 
The heart is a muscular 
electromechanical organ that 
pumps blood through the body. 
It consists of four chambers; two 
atria that act as reservoirs for 
two ventricles. The 
endocardium is the innermost 
lining of the chambers, the outer 
layer of the cardiac muscle is 
the epicardium with the 
myocardium cardiac tissue in 
between. The whole organ is 
covered with a layer called pericardium.
1
 
A cluster of cells located above the right atrium, between the myocardium and 
the epicardium, called the sinoatrial (SA) node, acts as the heart's pacemaker, 
Figure 1: A schematic of the heart's structure. 
Red arrows indicate oxygenated blood and blue 
arrows indicate deoxygenated blood 
2 
 
producing regular electrical signals. The signal travels down the atria causing their 
contraction and depolarizes the atrioventricular (AV) node, which is another cell 
cluster in the center of the heart, between the atria and the ventricles. The electrical 
signal activated in the AV node travels down the wall of muscle between the right and 
left ventricles, known as the septum, through a bundle of fibers. At the apex of the 
heart, which is the very bottom of the heart, the bundle splits into left and right bundle 
branches that depolarize the left and right cardiac ventricles from the bottom-up, and 
cause their contraction
1
, as indicated in the schematics of Figure 1. 
At the start of a cardiac cycle, the ventricular chambers are in their relaxed 
phase, known as ventricular diastole. Blood low in oxygen, collected from the body, 
pours from the right atrium into the right ventricle. The ventricular contraction phase 
(systole) pumps blood from the right ventricle through the lungs, to obtain oxygen and 
to release carbon dioxide. Oxygenated blood returns to the left atrium and passes to 
the left ventricle (LV) in ventricular diastole. During systole, the oxygenated blood is 
pumped through the circulatory system to the rest of the body to circulate oxygen, 
nutrients, and hormones, and to collect waste. Blood flow direction is regulated by 
valves.
1
 
Cardiac muscle cells are among a class known as excitable cells, i.e. they 
actively respond to an electrical stimulus that initiates the heartbeat, and causing the 
flow of ions. Specifically, sodium (Na
+
), potassium (K
+
) and calcium (Ca
2+
) ions flow 
via cardiac cell trans-membrane ion channels.
2
 In a resting heart, the difference in ion 
concentrations between the interior and exterior of the cardiac cell maintains a 
negative trans-membrane potential.
3
 Chemicals or drugs interacting with these 
channels could cause partial or full ion flow inhibition, thus disturbing the 
electrophysiology and mechanical function of the heart.
3
 
B) Nanomedicine and the Heart 
Nanoparticles, which are nanomaterials of less than 100 nm in at least one 
dimension, are currently a very interesting area of scientific research. With their small 
size comes a multitude of highly desirable mechanical, optical, electrical and 
chemical properties, lending them well to being used in a variety of fields, including 
the biomedical field.
4
 In particular, nanoparticles have great potential in 
3 
 
nanomedicine, which can be defined as the diagnosis, treatment or prevention of 
diseases using nanoscale tools, such as sensors, imaging agents, drug delivery systems 
or the drug product itself.
5
 Of special interest is the use of nanoparticles as a drug 
delivery system (i.e. nanocarriers) to offer enhanced targeting of diseased tissues, 
increased permeability into diseased cells and controlled drug release.
6
 However, 
nanoparticles at times become a likely cause for unwanted toxicological reactions.
4
 
Their high surface area to volume ratio increases their reactivity, which can cause 
undesired biological interactions, while their small size allows them to cross 
biological barriers with ease, risking their translocation to unplanned targets, e.g the 
heart.
7
 
In fact, one of the foremost reasons for drug discontinuation at all phases of 
development is cardiotoxicity, in both cardiac and non-cardiac pharmaceuticals.
8
 
Cardiotoxicity can be defined as the occurrence of an electrophysiological 
dysfunction of the heart or a mechanical abnormality of cardiac muscular behavior as 
a result of the intake of a toxic matter.
9
 Cardiovascular safety concerns have been 
responsible for almost 19% of drug withdrawals in the United States alone, over the 
past 40 years, and for 9% of worldwide withdrawals.
8
 
Drug development and approval takes extensive time, money and effort, and is 
subject to high failure rates.
8
 In fact, many promising drugs pass the initial 
cytotoxicity (toxic to regular cells) screening only to turn out to be highly cardiotoxic 
in preclinical trials.
10
 Often, adverse drug effects on cardiac function appear only after 
completion of clinical trials, or after drug release in the market.
11
 Detecting adverse 
drug interactions at such a late stage could undoubtedly cause a negative impact on a 
patient's health and general consumer confidence. Thus, there is increasing interest to 
better understand drug-induced cardiovascular complications, and to predict 
undesirable side effects at as early a stage in the drug development process as 
possible. 
C) Nanoparticles Can Cause Cardiotoxicity  
Various nanoparticles, used as nanocarriers, have been associated in the 
literature with cardiotoxicity. The most commonly used materials for inorganic 
nanoparticles are metals and their compounds,
6
 where gold nanoparticles (AuNPs) are 
4 
 
one of the most extensively researched.
12
 Their easy fabrication, tunable size and 
shape, and ready functionalization endow them with unique physical, chemical and 
optical properties that render them attractive candidates for many diagnostic and 
theraputic applications
13
. Such applications include their use as nanocarriers for 
target-specific delivery, and controlled and sustained release of drug molecules
14 
.
 
AuNPs are particularly attractive in cancer research,
15
 especially ultrasmall AuNPs, as 
they are able to access cancer cell nuclei causing more damage.
16
 Problems of toxicity 
appear according to the size of the AuNPs and their applied functional groups.
7
 
Several studies in the literature have identified that triphenylphosphine monosulfonate 
capped ultrasmall AuNPs of 1.4 nm diameters (Au1.4MS) are highly cardiotoxic, due 
to the irreversible binding and blockage of K
+
 channels.
7,10,17
 
Similarly, silver nanoparticles (AgNPs) also play a part in nanomedicine, in 
areas such as biosensing and wound dressing, for their antibacterial properties. 
Increasing concentration of AgNPs was tested for its effect on excitable cells, and 
concentrations of 10
-5
 g/ml or higher were shown to have an inhibitory effect on the 
Na
+
 channel altering cellular electrophysiology.
18
 Quantum Dots are another widely 
researched material on the nanoscale that exhibit excellent imaging and cell tracking 
properties, but have a negative effect on the Na
+
 and Ca
2+ 
channel functionality.
19
 It 
has also been found that yttrium released from the growth catalyst of carbon nanotube 
has an inhibitory effect on  Ca
2+ 
channels.
20
 
On the other hand, oxide nanoparticles are widely used in production leaving 
the end user of the product subject to accidental exposure to the nanoparticles 
through, for example, inhalation or skin contact.
21
 Certain oxide nanoparticles have 
also been associated with cytotoxicity. Copper Oxide (CuO) nanoparticles have had 
their biological effects tested, where they were found to influence the K
+
 current in 
cells, and in turn induce cell inactivation.
22
 In a later study, CuO nanoparticles were 
found to also affect cellular Na
+
 concentrations, due to their inhibitory effect on the 
Na
+
 channels.
23
 Furthermore, zinc oxide (ZnO) nanoparticles, have shown great 
potential for many applications, including electrical, environmental and, more 
recently, biosensing
24
. However, a concentration of 10
-4
 g/ml or more has been shown 
to activate Na
+
 channels, thus affecting intracellular ion concentrations and cell 
excitability.
25
 ZnO nanoparticles have also been found to have an inhibitory effect on 
Ca
2+
 entry into the cell.
21
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D) Typical Quantifiers of Cardiotoxicity 
We note that most of nanomaterials have been tested for their effect on 
excitable neural cells, but not yet for their effect on excitable cardiac cells, which this 
study aims to do. 
For an  
electrophysiological assessment 
of risk from new drugs, in 
general, the most commonly 
used biomarkers are based on 
electrocardiogram (ECG) 
measurements, especially the 
QT interval shown in Figure 2. 
ECG refers to electrode readings 
over time of the electrical activity of the heart, measured off the body surface. The QT 
interval is then the time interval between ventricular excitation (Q-wave) and end of 
repolarization (T-wave). The QT interval should be less than or equal to 400 ms for an 
average heart rate of 72 beats per minute.
26
 
Drugs that prolong or shift the QT interval are considered especially risky and 
their development is generally discontinued.
27
 This is because QT interval alteration 
induces disturbances  in ventricular contraction patterns and blood Ejection Fractions 
(EF), both which compromise heart function. Ventricular strain and EF are thus the 
commonly observed biomarkers for drug development and identification of 
cardiotoxicity.
28
 
E)  Assessing the Risk of (Nano-) Drug Cardiotoxicity 
Many experimental studies have been carried out to investigate cardiotoxicity 
induced from ion channel blockage. Preclinical studies of drug candidates have 
evolved over the years to include in-vitro assessment of their electrophysiological 
effect on cardiomyocytes, using a voltage-clamp or patch-clamp technique, which is a 
lab technique that measures electric current of single or multiple cell membrane ion 
channels.
10,29,30
 Animal test subjects have also been used for in-vivo assessment of 
blood pressure, heart rate and ECG.
11,31
 However, it has been determined that ion 
Figure 2: Pseudo ECG of normal heart 
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channel currents in cardiomyocytes and their response to drugs is species-specific, and 
that even subtle changes in the elctrophysiological response to drugs between human 
and nonhuman cells can lead to different organ behaviors, due to the nonlinearity of 
the systems.
32
 
To minimize potential risks from cardiotoxicity, much research has focused of 
recent on cardiac modeling and simulation, which are becoming an increasingly 
popular alternative to clinical and experimental (in-vitro) studies on the human heart. 
Modeling and simulation, or in-silico testing, promise a new predictive capability of 
biomarkers, for the rigorous evaluation of cardiotoxicity. In-silico methods are 
especially sought for, due to their greater safety and their ability to shed light on basic 
phenomena, which arise from the chemistry, biology, electrophysiology and 
mechanics of the heart, as well as their prediction of the overall behavior of the heart 
resulting from the multiscale and multiphysics interactions between such basic 
phenomena.
33
 The Food and Drug Administration (FDA) listed the need for the 
development of mathematical and computational models as risk-benefit predictive 
tools for nanomedicine research.
34 
Such models can however only be valuable, when 
their predictions compare closely to clinical data and biomarkers. 
F)  Computational Methods for Predictive Assessment 
  Toward achieving such close comparison between in-vivo and in-silico, a 
number of human action potential models have been put forward in the literature, 
each aiming to accurately describe the cycle of depolarization and repolarization of 
single human cardiac cells. Common to these models is that they lay coupled systems 
of ordinary differential equations (ODEs), for a description of ionic channels, 
exchangers and pumps, which collectively cause an action potential and regulate 
cellular sodium, potassium and calcium concentrations and fluxes.
35–37
 
 Such single cell models alone have been found inadequate for the prediction of 
clinically accurate ECG measurements. This is because single cell models necessarily 
ignore cardiac muscle fiber (myofiber) orientation, and surrounding tissue 
conductance, in generating and controlling the action potential. Multi-cell models 
have thus been developed, which combine single cell models as one, two or three 
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dimensional fibers and sheets, so as to better simulate the effect of single or multiple 
ion channel blocks.
38,39
 
More recently, advanced models have been introduced to relate drug effects on 
cardiac electro-physiology.  For instance, the Cardiac Safety Simulator (CSS) is a 
commercial tool, made available from Certara, developed for the testing of ion 
channel activity, with population variability which adds the likely impact of age, 
ethnicity and gender. It has been found to be able to predict the average effect of drugs 
on ECG and QT change. However, insufficient studies have been carried out using 
this tool to accurately confirm its predictive performance.
28,40,41
 Nonetheless, evidence 
suggests cardiac electro-physiological models are rapidly advancing, having evolved 
from single cell predictions, to large scale models embedded in the torso, or even 
whole body geometries with body surface potentials, where single and multiple 
channel blocks can be recorded, analyzed and compared.
26,42–44
 
Very recently, these sophisticated electro-physiological models have been 
integrated with cardiac mechanics simulators, in a multiphysics computational 
framework. This effort has been motivated by a need to investigate drug-induced 
changes to cardiac muscle intractability, which can have dangerous repercussions for 
patients. These changes are particularly difficult to measure clinically, making in-
silico testing especially relevant. A few studies have been published, aiming to capture 
the multiscale interactions that characterize human cardiac electromechanics, from the 
drug and cell levels to the organ level.
33,45
 Some studies are now focused on building 
a model for the complex fiber orientation of the cardiac walls, in order to properly 
capture that rotation and twist of the LV, and use the quantification and interpretation 
of LV torsion as a potential clinical tool.
46,47
 In fact, LV twist is an important 
phenomenon that plays a significant role in blood ejection, and has, until recently, 
been somewhat neglected in the field of cardiac mechanics.
48
 Fewer models have 
been built for both right and left ventricles.
49–51
 Other models aim to develop the most 
accurate material law describing the material properties of cardiac tissue, both active 
and passive (with respect to electrical excitation), and to accurately predict 
corresponding stresses, strains and volume change from cardiac contraction.
52,53
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The largest ongoing cardiac electromechanical modeling project is the Living 
Heart Project
1
. It is a whole heart model developed by Simulia, through a consortium 
of researchers, clinicians and international industries, to create a unified foundation of 
cardiac electromechanical modeling and simulation. Their successful combination of 
accurate heart geometry and material properties in a multiscale/multiphysics 
framework is beginning to produce rather realistic predictions in normal and abnormal 
cardiac behavior.
50,51
 This project, however, has not yet included drug interaction 
effects in their electrophysiological models. 
 In a parallel vein, the challenge of constructing patient-specific geometric 
models of the heart, capturing any abnormalities in form, from medical images and 
clinical data, is also receiving much research attention.
54,55
 This effort aims to 
improve diagnosis of cardiac diseases, understand the variation of disease across 
patients, and predict patient-specific response to alternative interventions and medical 
treatments. 
Such advances in electromechanical modeling are thus increasingly becoming 
an asset to the field of cardiac surgery, by reproducing the effects of heart diseases, 
simulating surgeries, predicting stress and strain, and quantifying changes in tissue 
material parameters.
56
 Nevertheless, linking these state-of-the-art electromechanical 
methods, mostly available as research codes in testing, to drugs and the assessment of 
drug-safety has not taken root yet.
28
 This points to a fertile ground for a computational 
multiphysics exploration, to lend its reliable hand to the safe advancement of 
nanomedicine. 
G) Objectives of this Thesis 
 It is the objective of this work to link a detailed account of cardiac myofiber 
mechanics to drug-induced electro-mechano-physiology. Specifically, this study aims 
to setup a computational model of the human ventricles, which integrates nanoscale 
ionic flow from myocytic currents, exhibits the chemical interference of drugs and 
nano-drug carriers, captures resulting macroscale electrical propagation across 
ventricular tissue and resulting tissue contractile behavior, and accurately predicts 
associated electrical and mechanical biomarkers. In order to do so, a material law that 
                                                 
1
http://www.3ds.com/products-services/simulia/solutions/life-sciences/the-living-heart-project 
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governs orientation-dependent tissue deformation is developed, based on the 
Holzapfel and Ogden
53
 model, and is programmed in this study on the open source 
software package Chaste. 
H) Why Chaste? 
 Chaste
2
 (Cancer, Heart and Soft Tissue Environment) is a C++, object oriented 
library developed by the Computational Biology Group in the Department of 
Computer Science at the University of Oxford. It incorporates a broad set of 
numerical solvers and state-of-the-art algorithms
 
for the service of biological 
modeling.
57,58
 Its ionic and reaction-diffusion models have been verified and 
extensively used for cardiac electrophysiological modeling.
26,38,39,42,44,59
 As it is an 
opensource software, its components are in a constant state of development. 
 The selected material law we developed on Chaste describes hyperelastic 
tissue properties that incorporate myofiber and sheet directions in the passive stress 
tensor. The material model is herein extended to implicit time integration by 
formulating an appropriate Jacobian (fourth-rank elasticity tensor). Coupling between 
the ionic, electrophysiological and mechanical models is then implemented on 
Chaste’s multiphysics solver, as discussed in57,60, to unveil new insights into the 
influence of drugs on the heart, ultimately advancing the field of computational 
nanomedicine. 
I)  Organization of the Thesis 
 This thesis is organized as follows. In section 2, we go through the 
methodology starting with the electrophysiological models in Chaste that are used in 
the simulations describing the electrical activity in a single cardiac cell and in the 
whole organ. After that we move on to the mechanical response discussing the fiber 
orientation in more detail as well as the active contraction model and passive material 
models of the mechanical behavior followed by how the coupling of these different 
components is carried out in Chaste. In section 3, the results of the 
electrophysiological simulations on an anatomically detailed ventricular mesh and the 
results of the coupled models are presented under normal conditions, under the effect 
                                                 
2
http://www.cs.ox.ac.uk/chaste/ 
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of a Na
+
 channel blocker , under the effect of ultra-small gold nanoparticles on the K
+
 
channel and under the effect of a Ca
2+
 channel blocker. We conclude by summarizing 
our current findings and discussing potential future research directions in section 4. 
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2) Methodology 
A) Electrophysiology 
 The flux of ions and associated electrical activity of an individual myocyte are 
essential phenomena to be modeled in cardiac electrophysiology; these may in general 
be well characterized by the various cell models available in literature.
35–37,61,62
 Cell 
models must then be linked to governing differential equations that are responsible for 
the propagation of electrical activity across cardiac tissue.
63 
i) Cellular Level Models of Electrical Activity 
Embedded protein structures on cell membranes form channels, exchangers  
and pumps responsible for the passage of ions in and out of the cell. Each protein 
structure is specific to one or two ions, responding to changes in potential across the 
cell membrane known as trans-membrane potential. Balancing the flow and 
intracellular concentrations of sodium (Na
+
), potassium (K
+
) and calcium (Ca
2+
) ions 
is regulated by the opening and closing of these channels, and their generation of an 
action potential. The cardiac action potential is the sharp activation and the slow 
repolarization of the cardiac cell membrane.
63
 The normal cycle shown in Figure 3 
consists of 5 phases. The rapid depolarization (Phase 0), the early/rapid repolarization 
(Phase 1), the plateau (Phase 2), the late repolarization (Phase 3) and the resting phase 
(Phase 4).
2
 In particular,
 
in resting tissue the difference in intracellular and 
extracellular ionic concentrations amounts to a negative trans-membrane potential. 
Application of a significant electrical stimulus (e.g. incoming from pace-maker cells) 
then leads to the depolarization of the trans-membrane potential, by activating the 
Na
+
 channels, which allow Na
+
 into the cell. A positive trans-membrane potential, on 
the other hand, activates the Ca
2+
 and K
+
 channels, which pass Ca
2+
 into the cell and 
K
+
 out of the cell, resulting in a plateauing of the action potential. A rise in 
intracellular Ca
2+
 concentration instigates myocytic contraction, while the fall in 
intracellular K
+
 concentration repolarizes the trans-membrane potential back to its 
negative resting value.
3
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Figure 3:  Normal action potential generated by membrane currents 
Corresponding mathematical descriptions of this electrical activity in 
myocytes are all based on the work introduced by Hodgkin and Huxley
61
 in the 1950s, 
where they described the trans-membrane potential and the cell membrane 
permeability, using just four ODEs. Models incorporating more cell properties and 
variables were later developed to increase their accuracy and strengthen their impact.
 
In general, an ionic model needs to be detailed enough to model the properties of a 
single myocyte, but maintain computational efficiency, which is required for large 
scale simulations (of the whole heart).
63 
One of the most extensively used ionic models in literature
26,39,41,43,64,65
 is the 
TenTusscher and Panfilov human action potential model.
35,66
 It has been verified as an 
efficient model with reliable results based on experimental data.
36,67
 It combines the 
15 major ionic channels of the human ventricular cardiac myocyte, which consist of 
10 transmembrane channels, 3 intracellular calcium channels, 1 sodium-potassium 
exchanger (INaK) and 1 sodium-calcium pump (INaCa) as shown in Figure 4. The cell 
membrane ionic currents modeled are the fast Na
+
 current (INa), the L-type Ca
2+
 
current (IcaL), the background Na
+
 and Ca
2+
 leakage currents (IbNa, IbCa), the plateau 
Ca
2+
  and K
+
 currents (IpCa, IpK), the slow delayed rectifier current (IKs), rapid delayed 
rectifier current (IKr), the inward rectifier K
+
 current (IK1) and the transient outward 
current (Ito). Differences in the Iks and the Ito differentiate between epicardial, 
endocardial and mid-wall cells giving more accurate electrical conduction 
patterns.
35,63
 The intracellular Ca
2+ 
dynamics, which are a crucial link between the 
electrical activity and the cell contraction, are modeled by the leakage current from 
13 
 
the sarcoplasmic reticulum (Ileak), the calcium-induced Ca
2+
 release current (Irel) and 
the pump current taking up Ca
2+
 into the sarcoplasmic reticulum (Iup).
35
 We will use 
the TenTusscher and Panfilov human action potential model
66
 (TP06) in the 
simulations of this study which is a reduced, more efficient version derived from the 
original model. The sum of all the trans-membrane ionic currents (Iion) computed from 
TP06 will then be passed on to solve the electrophysiological field equation. 
 
Figure 4: Diagram of ion movement across cardiac cell membrane and 
sarcoplasmic reticulum as described by the Ten Tusscher and Panfilov model 
ii) Capturing Drug Interaction 
 There are two basic ways certain drug molecules can cause ionic flow 
inhibition by binding to ion channels. The first is when binding occurs near a 
channel’s opening, which results in a physical barrier in the path of ionic flow. The 
second is a structural change induced in ion channel proteins due to drug binding, 
which also leads to ionic flow restriction.
3
 In both cases a modification may be 
imparted to the TP06 action potential to model the inhibitory effect on Na
+
 and K
+
 
channels of drugs in relation to dosage, half maximal inhibitory concentration (IC50), 
and the Hill coefficient.
26
 Hill coefficient is a quantification of the affinity of 
molecules or ions to bind to an already bound receptor. A value of more or less than 
one indicates that molecules or ions bound to a receptor increase or decrease, 
respectively, the likelihood of other molecules or ions to bind to that receptor, while 
having a Hill coefficient of one means the binding affinity is unaffected by the 
receptor's state, bound or unbound.
3
 In particular, for the TP06 ionic model, the effect 
14 
 
of an investigated drug will be accounted for by altering ionic conductances (g) in the 
action potential model. The following formula is often used, with Hill coefficient n = 
1;
42
 
           
 
   
   
    
  
     (2.1) 
In equation (2.1) the degree of channel blockage is made dependent on the dosage [D] 
and IC50 of the drug. Index j represents the targeted ion channel.
26
 
iii) Computational Implementation 
 CellML was used for the implementation of the aforementioned cell model. 
CellML is an XML-based language developed to provide a defined form and common 
basis for the development of mathematical cell models, with an aim to avoid errors 
that might arise in the exchange channel between researchers, during translation from 
one programming language to another, or from poor documentation. CellML 
facilitates the process of integrating selected cell models with different simulation 
environments. In particular, PyCML is a Python CellML tool integrated in Chaste that 
generates C++ classes from cardiac cell models linked to the electromechanical solver 
in Chaste.
68
 
 As the system of ODEs representing the cardiac cell has a 'stiff' nature, due to 
the very fast upstroke of the action potential compared to the remaining simulation 
activities, a special solver is required.
68
 CellML does not specify how the system of 
ODEs should be solved, leaving the choice to the users. In Chaste, the user could 
either code their own solvers or use PyCML to link to the CVODE library provided 
by Sundials3 to solve stiff ODE systems.
69
 
iv) Tissue Level Models for Electrical Excitation and Recovery 
 Modeling the entire organ (the heart) cell by cell would be too 
computationally expensive, so a continuum approach is usually adopted to conduct 
simulations on this physiological scale. The idea is to avoid modeling the cellular 
scale explicitly by instead studying volume averaged quantities for cells, which are 
small enough compared to the overall heart domain, and may thus be treated as points 
in a continuum.
63
 The corresponding continuum field equations which need to be 
                                                 
3
https://computation.llnl.gov/casc/sundials/main.html 
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solved (numerically integrated) to simulate electrical excitation and recovery across 
ventricular tissue go by the name the bidomain model.
70
 
 The bidomain model was developed in the 1970s
71
 and set the benchmark for 
studying electrophysiology of the heart. It divides the ventricular system into 
intracellular and extracellular domains. Cardiac cells are then assumed to be 
electrically connected to allow an electric stimulus to propagate throughout the heart 
via a gap-junction mechanism.
63
 
 We note that cardiac tissue is microstructured, so that corresponding electrical 
properties are in general anisotropic. The microstructure of ventricular tissue is 
discussed later in fuller detail. Nonetheless, we here must recognize that cardiac tissue 
is in fact organized in lateral sheets of fibers, and that tissue conductivity is higher 
when stimulated parallel to the alignment of its myocytes than when perpendicular. As 
such, at each given point three distinct values for conductivity are assumed; along the 
fibers (σf), along the sheets but perpendicular to the fibers (σs), and perpendicular to 
both the fiber and sheet directions (σn). This assumption gives rise to two diagonal 
conductivity tensors, one for intracellular conductance (Di) and one for extracellular 
conductance (De), of the form:
63,70
 
     
    
    
    
     
(2.2) 
 The bidomain model can be significantly simplified into the monodomain 
model by addressing the trans-membrane potential on the whole, and assuming 
anisotropy between intracellular and extracellular conductances are related by the 
equation σe = λσi, where λ is a scalar constant. An effective conductivity for the 
monodomain equation thus substitutes the two conductivities of the bidomain 
equation as follows: 
   
 
   
       (2.3) 
 Furthermore, extracellular applied current I
e
applied from the bidomain equation 
also changes in the monodomain equation to
70
: 
        
          
   
 
  
    
     (2.4) 
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 For the simulations herein, the monodomain equation was selected to provide 
the electrical image of cardiac tissue over a cardiac cycle. It is less computationally 
demanding than the bidomain model, and gives sufficiently accurate results with 
respect to electrical propagation and ionic channel blocking
72
. It is thus also assumed 
adequate to drive the associated cardiac mechanical cycle, which is the focus of the 
modeling effort developed in this work. The governing monodomain equation can be 
expressed as: 
 
   
  
           
              
  
   (2.5) 
where χ is the surface-area-to-volume ratio, Vm is the trans-membrane voltage, t is the 
time, Cm is the capacitance across the membrane, DM is the effective conductance 
tensor, Iapplied is the applied stimulus and Iion is the value passed on from the TP06 
ionic model, representing sum of all the trans-membrane ionic currents.
73
 
v) Computational Implementation 
 As a parabolic partial differential equation (PDE), equation (2.5) requires a 
simple linear parabolic solver, which is predefined on Chaste. The solver employs the 
finite element method (FEM). The weak form of the monodomain equation is obtained 
by multiplying it by basis functions (ϕ), one for each node of the cardiac model, such 
that these functions satisfy the Neumann boundary condition, which for the case of 
the monodomain equation requires that their derivatives on the heart surface be zero, 
i.e. that no electrical flux out of the heart would be permitted.
74
 
 The discretized form of the problem becomes
74
 find V
m+1
 where; 
 
  
  
         
  
  
               (2.6) 
M is the mass matrix and K is the conductance dependent stiffness matrix given by; 
          
             σ     
     (2.7) 
F
m
 is a vector of body current and stimuli for each node, and c
surf  
is a vector of 
surface stimuli for each node, which in this case is set to zero. These vectors are 
defined as follows: 
  
                         
            
 
  
     
  (2.8) 
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vi) Cell-level and Tissue-level Model Coupling 
 Once an external stimulus is 
applied to the cardiac tissue, the 
corresponding  change in trans-membrane 
potential is communicated to the ionic 
model to solve for the associated ionic 
flow through the myocyte channels, 
pumps and exchangers. In the subsequent 
timesteps there is a back and forth 
relationship between the two models, as shown in Figure 5. The current (Iion) 
calculated by the ionic model is fed to the monodomain reaction-diffusion equation, 
and the voltage and calcium concentration are updated as state variables which affect 
the ionic concentrations and current flow on the cellular level.
Figure 5: Excitation/Recovery model 
and ionic model coupling 
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B) Tissue Mechanics 
i) Ventricular Fiber Structure & Relevance to Tissue 
Mechanics 
 Modeling living soft tissue mechanics is a topic of interest in much ongoing 
international research for a variety of reasons. If we confine our vision to cardiac 
research, however, a rigorous investigation of tissue mechanics holds promise in the 
prediction of ventricular volume changes between cardiac contraction and relaxation,  
a monitory of cardiac wall thickness variation, a quantification of ventricular twist 
and other related phenomena, all which will enable a deeper understanding of the 
different mechanisms that govern healthy and unhealthy heart functions.
75
 
  The heart however has a complex structure, composed of a multitude of fibers 
laid out along different orientations, which are crucial to defining electrical 
propagation
76
 and mechanical contraction patterns.
49
 Fiber distribution in general 
evolves smoothly from a right-handed helix structure in the sub-endocardium (Figure 
6A) to a left-handed helical structure in the sub-epicardium (Figure 6B). The 
opposition in fiber direction between the sub-epicardium and the sub-endocardium 
compels them to contract in different directions. The larger radius of rotation of the 
outer epicardial layer dominates the direction of rotation causing twisting and 
shearing in the endocardium fibers where strain energy is thus stored and which, when 
released, serves for diastolic recoil.
77 
 
Figure 6: Fiber distribution evolve from a right-handed helical structure in the 
subendocardium (A) to a left-handed helical structure in the subepicardium (B) 
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Models of the ventricles that do not capture fiber direction have been found to 
lead to a misdistribution of stresses and strains, a decrease in cardiac energy 
efficiency, and an overall compromise in the accuracy of the predicted cardiac 
electromechanical phenomena.
75,77
 Hence, proper myofiber orientation modeling has 
been a main focus of this work. 
ii) Myofiber Orientation Modeling  
 The first to analyze the continuous change of fiber angle through the 
ventricular wall and the alterations in the fibers between systole and diastole were 
Streeter, et al.
78
 Their model was built from histological datasets, relating well to the 
observed physiology of the ventricles, thus remains to date the most widely used fiber 
orientation model in cardiac simulations, in spite of its simple form.
79 
In this model, a 
fiber axis is assigned to each element in the ventricular mesh by means of helix angle, 
α, according to the following80; 
α = R * sign(1 – 2d) |1 – 2d| n           (2.9) 
where d is transmural depth and ranges from 0 to 1 from endocardium to epicardium; 
R is maximum absolute value of α depending on heart region (see next paragraph), 
such that α ranges between R at the epicardium and –R at the endocardium of a given 
region, n modulates the transmural variation of α, e.g. linear (n=1) or cubic (n=3). The 
sheet axis is then defined as lying in the perpendicular plane to the fiber axis assigned, 
and the normal axis is finally defined as the direction orthogonal to them both.
53
 
 Simple heart region models merely differentiate between the left ventricle 
(LV) and the right ventricle (RV); while more accurate models could differentiate 
between 16 myocardial regions of the LV on one hand, and the apical, mid and basal 
regions of the RV on the other.
46
 
In this work we thus employed the Streeter model to generate fiber 
orientations in the LV and RV, as indicated in Figure 7, having only distinguished two 
heart regions: the LV (Figure 7A, 7B) and RV (Figure 7C, 7D) for simplicity. 
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Figure 7: Fiber Orientations generated by the Streeter model. A) LV 
endocardium, B) LV epicardium, C) RV endocardium, D) RV epicardium 
 
iii) The Mechanical Behavior of Myofibers 
Modeling living soft tissue mechanics is a topic of interest to help monitor the 
change in cardiac wall thickness, myofiber structure and ventricular volume between 
contraction and relaxation to enable deeper understanding of the different mechanisms 
that govern behavior of healthy and unhealthy hearts.
75
 
Two components are necessary to understand the electromechanical 
deformation of myofibers accurately. The first component is due to an active cellular 
contraction, i.e. an electrically excited contraction, which is responsible for the 
generation of an active tension in the myofibers. The second component, on the other 
hand, characterizes a passive myofiber mechanical response
60
, i.e. one intrinsic to 
myofiber protein elasticity. 
Under a microscope, a muscle fiber can be seen to be composed of many 
myofibrils, each consisting of repeated cylindrical sarcomeres, as summarized in 
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Figure 8A. A sarcomere is 
comprised of contractile 
proteins, bounded by Z-disks 
(Figure 8B). In particular, thin 
filament proteins, which are 
made up of helically arranged 
actin monomers (tropomyosin 
and troponin)  project from both 
sides of Z-disks. Furthermore, 
myosin thick filament proteins 
are located in the middle of the 
sarcomere, connected to Z-disks 
via very thin, elastic filaments. In 
a contracting muscle fiber, an 
interaction between thick filament 
myosin and thin filament actin 
binding sites leads to a sliding action.
81 
 
Figure 9: The total contractile force developed during contraction generated by 
the sum of active and passive forces 
 
In particular, no active force is developed, as seen in the plot of the active 
force in Figure 9 at (a), when a sarcomere is stretched far enough to eliminate overlap 
between filaments (Figure 10a), as no cross bridges can form. Changes to the trans-
Figure 8: A) Muscle fibre composed of 
repeating myofibrils, B) Cylindrical Sarcomere 
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membrane potential lead to a release 
in Ca
2+
 ions, which bind to troponin 
on the thin filament changing its 
structure to expose binding sites and 
enable the formation of a cross 
bridge between myosin and actin 
(Figure 10b). These cross bridges 
cause shortening of the muscle fiber 
by exerting longitudinal forces that 
increasing the overlap between the 
thick and thin filaments, and result in 
increased active contracting force as 
seen at (b) in Figure 9. However, as 
the shortening progresses, thin 
filaments begin to overlap (Figure 
10c, 10d) leading to a decrease in 
potential binding sites, and result in 
decreased active force (Figure 9 at (c) and (d)). When thin filaments hit the Z-disks 
they push back against the contractile force (Figure 10e), and net active force 
becomes zero (Figure 9 at (e)). Maximum force is thus produced when the sarcomere 
is at its intermediate length, while no force results at either extreme of length.
54
 
On the other hand, a passive force is present in the muscle irrespective of 
electrical excitation due to the (nonlinear) elasticity of connecting filaments in 
myofibers and the collagen connective tissue surrounding each muscle fiber. The 
active force generated by the cross bridges is independent of the passive force from 
elasticity. Thus the active and passive stresses could be superimposed to get the total 
force curve, as shown in Figure 9.
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iv) Active Stress Model 
 To capture myofiber mechanical response to electrical excitation at each 
material point, a calculation of the active tensile (Cauchy) stress tensor, σa, is needed. 
Active stress in general depends on the voltage, the intracellular calcium 
Figure 10: Different stages of stretch and 
compression of a sarcomere during 
contraction 
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concentration, [Ca
2+], fiber stretch state ( ), and sometimes the fiber stretch-rate   , in 
addition to any potential set of state variables.
60
 
The Kerckhoff model
82
 is a good example of a widely used active stress model. 
It contains no rate dependence, and no state variables, beyond [Ca
2+
], contributing to 
desired model simplicity. It nonetheless adequately connects to cellular chemistry 
changes, through ionic flux interaction with [Ca
2+
]. Due to our interest in nano-drug 
effects on cardiac electromechanics in this work, we are thus satisfied with this rather 
simple active stress model. 
 In this model, first a coefficient of the Cauchy active tension (  ) is computed, 
which depends functionally (say, function f1) on the time elapsed since electrical 
depolarization (ta), sarcomere length (ls) and contractile length (lc) as follows
82
; 
                
  
   
                              (2.10) 
where ls0 is the reference sarcomere length and Ea is the stiffness of the elastic 
filament. The function f2 describes active stress dependency on contractile length, 
while the function f3 describes active stress dependency on electrical activation time 
and the sarcomere length. These two functions are listed below: 
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  (2.12) 
where T0, a6 and a7 are active material parameters and tmax, td and tr are activation 
duration, activation decay time and activation rise time, respectively. 
 To construct the active stress tensor (  ), fiber direction vectors (f), defined in 
the current configuration, are introduced as dyadic bases for the coefficient computed 
in equation (2.2). This approach permits directional dependence of active stress in the 
model. Pulling back to the undeformed configuration, an active second Piola-
Kirckhoff (PK2) stress tensor (Tactive) can be recovered as follows
74
, 
        
   
  
          (2.13) 
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 This pullback operation is necessary to satisfy force equilibrium in the finite 
element solver on Chaste, which uses a total Lagrangian formulation. In equation 
(2.13) above, J is the determinant of the deformation gradient F, and f0  is the fiber 
orientation in the initial (reference) configuration. 
v) Passive Stress Model 
 In this study, we will make the usual assumption that myofibers are 
hyperelastic and that their mechanical response is orientation dependent.
53,78
 
Viscoelastic and poroelastic effects are thus ignored, and heart muscle is treated as 
incompressible. An isochoric (constant volume) strain energy function may thus be 
introduced as follows
83
; 
Wiso = W(u) – p(I3 - 1)     (2.14) 
where W(u) is a strain energy density function of displacement u, and describes 
mechanical response to both volumetric and isochoric deformation. p is a Lagrange 
multiplier, which may be interpreted as a hydrostatic pressure that penalizes volume 
change to enforce isochoric deformation. 
a) Holzapfel and Ogden constitutive law 
 The strain energy function developed by Holzapfel and Ogden
53
 is used in this 
study to compute the passive stress. It is an orthogonal components model based on 
shear and biaxial tests performed on a cube of passive myocardium tissue. It can 
capture the dissimilar responses of a material in the fiber f, sheet s and normal n 
directions. The strain energy function W(u) is written as
53
; 
     
 
  
              
  
   
               
 
    
     
 
   
    
            
     
 (2.15) 
where  a, af, as, afs, b, bf, bs and bfs are experimentally fitted parameters, and d = 3 in 
3D models. I1, I4 and I8 are invariants of the right Cauchy-Green strain (C = F
T
F), 
where F = F(u) is the deformation gradient depending on displacements u of in the 
neighborhood of material point. I1 is the sole isotropic term included in the energy 
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density function. I1 = tr(C), with tr the trace operator, is thus considered to 
characterize the behavior of the non-muscular, non-collagenous part of the tissue.
53
 
 Anisotropy was introduced in equation (2.15) by specifying one or more 
directions of reference, labeled i, and defining the I4 invariant in that direction 
according to I4,i = vi.C.vi, where vi is a vector pointing in direction i. The exponential 
function applied to the fourth invariant in the fiber (I4,f) and sheet directions (I4,s) is a 
good reflection of the high stiffening and energy storage behaviors of muscle fibers 
and connecting collagen fibers, respectively. The other invariant included in the strain 
energy density function is the coupling invariant (I8,fs = f0
.
C
.
s0), for a more detailed 
reflection of myofiber inter-dependency of orientations. 
 We here also note that the I2 invariant was deemed unnecessary to include in 
equation (2.15) by Holzapfel and Ogden, while the I3 invariant was omitted for 
incompressible tissue behavior, since J = 1 and  I3 = J
2
 = 1.  The I4 invariant of the 
normal direction (I4.n) was further shown to be dependent on I1, I4,f and I4,s, so that its 
inclusion was also unnecessary. Finally, only a coupling of the fiber and sheet 
directions associated with fiber stretch was included in equation (2.15), as it was 
observed that the shear response in the planes containing the normal direction are 
relatively low, and rather similar for both the fiber-normal and sheet-normal planes.
53
 
 The derivative of the energy function W with respect to C is then taken to 
obtain the PK2 stress, T(C, p), yeilding
74
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where, 
     
  
 
 
 
             
                                                                        
       
                                                                        
       
                                                           
         
   
 (2.17) 
and I is the identity tensor. 
When this model is setup for static finite element solvers, the corresponding Jacobian 
(iteration matrix) is needed
74
, and we derive it in this work as follows; 
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        (2.18) 
Where E is the Green-Lagrange strain tensor, and is the strain measure of choice in 
Chaste, which employs the total Lagrangian formulation, wherein E is energetically 
conjugate to PK2. 
 This Holzapfel and Ogden can be reduced to a transversly isotropic model by 
reducing the parameters to only 4 parameters; a, b, af and bf, which were shown to 
still fit data sets on cardiac mechanics very well. Indeed, in this study, these four 
material parameters were used (setting all others to zero) based on one of the most 
recent studies by Baillargeon et al.
51
, which showed improved mechanical predictions 
on blood ejection fractions, than competing models with all 8 parameters.
50,83
 
b) Pole-Zero constitutive law 
 Nash and Hunter
52
 proposed a transversly isotropic material law based on 
biaxial tests performed on thin sections of passive myocardium tissue. The strain 
energy function is given as follow; 
        
   
 
            
    
   
 
            
    
   
 
            
    
   
 
            
    
   
 
            
    
   
 
            
 (2.19) 
where the k's, a's and b's are the material parameters and the E is the Green-Lagrange 
strain tensor (E = (C – I) / 2)) where C is the right Cauchy-Green strain and I is the 
identity tensor. 
 This constitutive model is already developed on Chaste, but it has not been 
chosen in this study to examine nanodrug effects as it has been found to give weak 
results in terms of ventricular volume change and ejection fraction as shown later on 
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in the thesis. Also, unlike the Holzapfel and Ogden model, it is limited to transverse 
isotropy and cannot model orthotropy.
53
 The biggest problem, however, with this 
model is the fact that it needs 18 material parameters. Having that many lineary 
dependent parameters makes them difficult to identify
84
 and sensitive to small 
changes in the data.
53 
c) Mooney-Rivlin constitutive law 
 The Mooney-Rivlin material law was derived from the work of Mooney
85
 and 
Rivlin
86
 in large elastic deformations in rubber-like isotropic materials. The strain 
energy function is given as; 
W(u)  =  c1 (I1 -  3)  +  c2 (I2  -  3)        (2.20) 
where I1 and I2 are the invariants of the right Cauchy-Green strain (C = F
T
F), where F 
= F(u) is the deformation gradient depending on displacements u of in the 
neighborhood of material point. I1 = tr(C), with tr the trace operator, I2 = 
 
 
[(tr (C))
2
 – 
tr(C
2
)]. c1 and c2 are the material parameters.  
 This material law is already developed on Chaste, but, as shown later, it gives 
weaker mechanical behavior compared to clinical data and compared to the other two 
constitutive laws investigated in this thesis. Its problem lies in the fact that it assumes 
the material behaves identically in all directions and does not take into account the 
fiber or sheet directions which is not the behavior of the cardiac tissue.
87
 Hence, this 
material law was not used in this study to investigate the effect of nanodrugs on the 
cardiac mechanical deformation. 
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C) Electromechanical 
i) Coupling Summary 
Multiscale electromechanical modeling (itself multiphysics) is required in this 
work, since coupling appears between different length and time scales of our model 
ranging from molecular myofilaments (length ≈ 1.5-3.5 µm) to the organ level 
(volume ≈ 280 cm3), and from rapid changes in ionic fluxes to the much slower 
muscle contraction. In summary, ionic models are first solved at the subcellular level, 
then ion concentrations are fed into the reaction-diffusion electrophysiological 
equation to study signal propagation across the organ, and into the active stress model 
to predict resulting mechanical deformation due to myofilament Ca
2+
 based 
activation.  This is followed by passive tissue mechanics solving, which updates the 
electrical model with fiber and sheet orientations and the stretch-activated ionic 
channels. Clearly then all levels have a direct effect on each other via parameter 
passing, as summarized in Figure 11. 
 
Figure 11: Components of the cardiac electromechanical model 
 
However, the feedback of the mechanical deformation on the electrical 
conductance was not accounted for in this work since it is very computationally 
expensive to apply on big meshes such as the one used here. It would be quite 
interesting to see the feedback effect and compare with and without it on a more 
optimized tissue mechanics solver. The feedback to the ionic model was also removed 
since implementing how the stretch affects the stretch-dependent ion channels is 
outside the scope of this work. 
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ii) Stress Model Implementation on Chaste 
When solving tissue deformation, at each instant inertial effects are neglected 
and the tissue is assumed to be in equilibrium. The weak form of the equilibrium 
equations needed to get the deformed configuration in the incompressible case using 
the finite element methods are as follows
74
; 
  
   
   
      
   
   
  
   
 
        
  
          
   
    
                             
 (2.21) 
                
                                (2.22) 
where T = Tactive + Tpassive, V0 is the subspace of deformations and W is the subspace 
of pressures,  0 is the density, b is the body force per unit mass and s is the surface 
force. Equation (2.22) is the incompressibility constraint.  Since gravity is neglected 
and there are no applied forces, the last 2 terms of equation (2.21) are zero giving the 
equilibrium equations for the incompressible volume the following form: 
 
   
                  (2.23) 
           (2.24) 
Mechanical deformation is solved for on a quadratic mesh where quadratic 
interpolation is used for solving the displacement over N nodes and linear 
interpolation is used for solving the pressure over M nodes making the overall number 
of unknowns in the 3D mesh 3N + M. 
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3) Results and Discussion 
A) Problem Setup 
The geometrical model used in this work is derived from CT data of the 
human ventricular chambers.
76,88
 The mesh is confined to the left and right ventricles 
only and meshed into 238,382 elements. Since the electrical and mechanical meshes 
have different requirements regarding element type and element size, different 
computational meshes are used for each. The electric mesh is a linear tetrahedral mesh 
composed of 49,658 nodes. On the other hand, the mechanics mesh is a quadratic 
mesh with 354,107 nodes, to avoid pressure instabilities.
89
 Both meshes are generated 
using Chaste.  
The simulations were run on an AMD Opteron server with 256 GB of memory 
on an Ubuntu 14.04 operating system. 
 
Figure 12: Basal view of ventricular model at time 1 ms highlighting the area of 
applied stimulus on the endocardium in A) the left ventricle and B) the right 
ventricle  
 
 Ventricular tissue was stimulated by -10,000 μA for 1 ms in the endocardium. 
Figure 12 highlights the locations where the stimulus was applied in the left (A) and 
right (B) ventricle endocardia. The monodomain reaction-diffusion equation was then 
solved in our simulations for 400 ms, to ensure complete activation and repolarization 
of the ventricles. The corresponding PDE solver on Chaste was called with a time step 
of 0.05 ms, Electrical conductivity along the fiber direction was set to 1 mS/cm and 
0.3 mS/cm along the sheet and normal directions. and a surface area to volume ratio 
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was 200. For the cell model, the ordinary differential equation (ODE) time step was 
taken as 0.01 ms.  
 Dirichlet boundary conditions 
were prescribed for our mechanics 
model, where the nodes at the very 
bottom of the left ventricular apex 
(marked in yellow on Figure 13) were 
fixed in space in all 3 directions, leaving 
the remainder of the mesh to deform 
freely. As mentioned earlier, Kerckhoff’s 
contraction model is used to calculate 
the active tension; its solver was called 
with a time step of 0.01 ms. Equations of 
equilibrium were then set to solve once 
every 10 ms.  
The Streeter fiber class on Chaste was used to generate the fiber, sheet and 
normal directions at each element in the mesh (cell-centered). The vectors defining 
the fiber and sheet directions are shown in Figure 14 A and B, respectively. This fiber 
definition is necessary for both the electrical conduction and mechanical deformation. 
 
Figure 14: Streeter A) fiber and B) sheet direction vectors mapped on the 
ventricular mesh 
 The post processing for this study was performed on Matlab
4
 and the 
visualization of the mesh, its fibers and its electromechanical properties on Paraview
5
. 
                                                 
4
http://www.mathworks.com/products/matlab/ 
5
http://www.paraview.org/ 
Figure 13: Dirichlet boundary 
conditions. Nodes at ( z < 0.3) marked 
yellow are fixed in x, y, and z directions 
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B)  Simulation under normal conditions (Control) 
i) Electrophysiology 
a) Pseudo-ECG 
 The ECG is the recording of the cardiac potential off the body surface. Instead 
of solving the expensive problem of a coupled heart-torso model, an approximation 
can be made, through an averaging of signal propagation and recording it via an 
electrode placed at a specified distance from the heart.
88
 This approximation is called 
the pseudo-ECG and a Chaste
 
post processing class
57
 has been used to calculate it 
using the following formula
90
; 
                       
 
 
        (3.1) 
where Φe is the extracellular potential at location (x’, y’, z’), D is the diffusion 
coefficient, Vm is the trans-membrane potential and r is the distance of the electrode 
from a source point (x, y, z) on the heart surface to the electrode position (x', y', z') 
such that; 
r = [(x – x')2 + (y – y')2 + (z – z')2]1/2    (3.2) 
 
Figure 15: Basal (A) and side (B) view of the ventricle model with the electrode 
position coordinates at (10, 10, 5) 
 
 In this study, the diffusion coefficient was set to 1 and the electrode was 
placed in the position specified in Figure 15 such that (x', y', z') = (10.0, 10.0, 5.0), a 
location comparable to the surface of the torso. The pseudo-ECG computed from the 
voltage is plotted in Figure 16 from the beginning of the QRS complex to the end of 
the T-wave (QT interval), to assess ventricular activation and repolarization.
91
 The 
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plot shows a good prediction of the QT interval, with a duration of a little over 350 
ms, which is well within the expected range.
26
 
 
Figure 16: Pseudo-ECG plot of QT interval under normal conditions 
 
b) Action Potential 
 The action potential (AP) generated by the ion flow through the cardiac cell 
membranes is recorded at each time step for every node in the mesh. The AP of a 
sample node is plotted in Figure 17 and it shows it undergoes the five phases of the 
cardiac activation and repolarization, and the action potential duration is under 400 
ms. 
 
Figure 17: Action Potential plot under normal conditions 
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 The total activation time, which is the time it takes for the excitation wave to 
propagate throughout the ventricles from the apical endocardium to the basal 
epicardial wall, is 77 ms. The ventricles completely repolarize at around 368 ms. All 
these values are consistent with the literature.
26
 Figure 18A further captures the 
electrical excitation wave at mid propagation from the apex to the base, corresponding 
to a time of 45 ms. Figure 18B then shows complete tissue repolarization at time 300 
ms. Conversely, Figure19A shows the map of activation times and Figure 19B the 
map of repolarization times for ventricles. All these predictions are again consistent 
with the literature.
26
 
 
Figure 18: A) Depolarization at t=45 ms, B) Repolarization at t=300 ms 
 
 
Figure 19: A) Activation time map, B) Repolarization time map 
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ii) Tissue Mechanics 
 The Kerckhoff contraction model was used to solve for the active tension, 
while the energy function proposed by Holzapfel and Ogden was used to generate the 
passive material stress. The passive stress and its Jacobian were developed using the 
C++ programming language, and intergrated on Chaste. The material is modeled as 
transversly isotropic by zeroing out 4 of the 8 material parameters. The material 
parameter values used herein are listed in Table 1, guided by a recent study due to 
Baillargeon et al.
51
, which showed improved prediction of blood ejection fractions. 
Table 1: Holzapfel and Ogden material parameters used in this study 
A af as afs b bf bs bfs 
0.33 0.25 0 0 7.08 5.34 0 0 
 
 For validation, our material 
model was run under the same 
conditions as, and compared against, 
the well-established transversly 
isotropic Pole-Zero material law, whose 
material parameters were proposed by 
Nash and Hunter
52
. Both models 
completed simulation of almost 90% of 
the cardiac cycle without difficulty,  
with our model running faster, reaching 
350 ms in 325h 32m and the Pole-Zero 
material law reaching 350 ms in 334h 
54m. After 90% of the cycle, both 
models exhibit instability in the mesh 
and diverge, prematurely ending the 
simulation. 
 To highlight the importance of 
the fiber orientation in the mechanical 
tissue deformation, our transversly 
isotropic material model was also 
Figure 20: Ventricular contraction of A) 
Holzapfel and Ogden model (solid pink) 
against Pole-Zero model (translucent 
green)and B) Holzapfel and Ogden 
model (solid pink) against Mooney-
Rivlin model (translucent purple) 
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compared against the isotropic Mooney-Rivlin material model with material 
parameters c1 = 2 and c2 = 6, as proposed by Nash and Panfilov.
87
 Unlike the 
transversly isotropic models, the Mooney-Rivlin model ran till the end of the 
simulation reaching 400 ms in 249h 12m. 
 Figure 20 shows the maximum ventricular contraction resulting from the 
models superimposed, with the solid pink representing the Holzapfel and Ogden 
model, the translucent green representing the Pole-Zero model (Figure 20A) and the 
translucent purple representing the Mooney-Rivlin model (Figure 20B). The models 
exhibit similar looking contractions, however the Holzapfel and Ogden model appears 
slightly more contracted, which is desirable.  
For a proper comparison, a side-by-side map of tissue deformation of the 
Holzapfel and Ogden model against the Pole-Zero model, colored by strain 
distribution and stress distribution, is shown in Figures 21 and 22, respectively. The 
strain and stress maps of the Holzapfel and Ogden model against the Mooney-Rivlin 
model are shown in Figures 23 and 24, respectively. The effective deviatoric stress 
and the effective deviatoric strain were calculated at each element of the mesh at 50 
ms intervals. The deviatoric component of the stress and strain tensors only accounts 
for the distortional element of the tensor without the volume change (as tissue is 
incompressible); deviatoric stress is calculated as follows: 
σ    σ   
 
 
   σ      (3.3) 
 
and the deviatoric strain as: 
         
 
 
          (3.4) 
 
The effective stress is then calculated as: 
σ     
 
 
σ  σ     (3.5) 
and the effective strain as: 
      
 
 
          (3.6) 
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Figure 21: Strain distribution maps of the Holzapfel and Ogden model on the left 
and the Pole-Zero model on the right at times A) 50 ms, B) 200 ms, C) 300 ms, D) 
350 ms 
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Figure 22: Stress distribution maps of the Holzapfel and Ogden model on the left 
and the Pole-Zero model on the right at times A) 50 ms, B) 100 ms, C) 200 ms, D) 
350 ms 
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Figure 23: Strain distribution maps of the Holzapfel and Ogden model on the left 
and the Mooney-Rivlin model on the right at times A) 50 ms, B) 100 ms, C) 250 
ms, D) 350 ms 
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Figure 24: Stress distribution maps of the Holzapfel and Ogden model on the left 
and the Mooney-Rivlin model on the right at times A) 100 ms, B) 200 ms, C) 300 
ms, D) 350 ms 
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Looking at the predicted strain maps of the Pole-Zero model compared to the 
Holzapfel and Ogden model, small differences appear in the basal area and on the 
surface, especially close to the time of 300 ms (repolarization), but both models are 
comparable in terms of strain distribution. For the stress distribution maps, however, 
the Pole-Zero model clearly exhibits higher stress levels than the Holzapfel and 
Ogden model throughout the cycle, which indicates a much stiffer response from the 
Pole-Zero model. 
As for the Mooney-Rivlin model, the strain appears to be much less 
pronounced than the Holzapfel and Ogden model while the stress appears to be much 
more pronounced. This indicates that the lack of fiber direction in the cardiac muscles 
leads to less tissue deformation and a stiffer response from the model.  
To further quantify the mechanical behavior predicted, and decide on which 
model is preferable to move forward with, several biomarkers are used, including; the 
ventricular volume, the ejection fraction, the left ventricle twist angle between the 
apex and the base, the longitudinal strain, and the radial strains. These are analyzed 
next. 
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a) Ventricular volume 
At each time step, to measure the volume 
enclosed by the ventricles (which is irregular), left 
ventricle and right ventricle endocardiac  nodes are 
first separated from the rest of the mesh, and then 
from each other. For the ventricular node sets, alpha 
shapes are formed where all the nodes are 
connected turning the hollow ventricle into a solid 
body that is divided into tetrahedrons as shown in 
Figure 25. They are used to define the correct 
shape of the irregular cavities of the ventricles and 
calculate the correct volumes using a ready 
developed Matlab code.
6
 
 Figure 26 plots the changing volume of the LV and RV through time, when 
using the Holzapfel and Ogden model, the Pole-Zero model, and the Mooney-Rivlin 
model. The starting volume of the LV and RV are 96.7 cm
3
 and 96.6 cm
3
. With the 
Holzapfel and Ogden model, the LV reaches a minimum volume of 69.4 cm
3
 at time 
190 ms and the RV reaches its minimum volume 75.5 cm
3
 at time 90 ms. As for the 
Pole-Zero model, the LV minimum volume reached is 78.7 cm
3
 at 200 ms and 
minimum RV volume of 84.7 cm
3
 at 90 ms. The Mooney-Rivlin model doesn’t show 
much volume difference from the Pole-Zero model with a minimum LV volume of 
80.5 cm
3
 at 200 ms and a RV volume of 85.4 cm
3
 at 190 ms. 
Hence the Holzapfel and Ogden model shows significantly more contraction 
than both the Pole-Zero and the Mooney-Rivlin models. Surprisingly, despite the lack 
of fiber and sheet directions, the ventricular volume reduction of the Mooney-Rivlin 
model is close to that of the Pole-Zero model which indicates that in terms of 
ventricular contraction it is not a bad alternative for the Pole-Zero model specially 
when accounting for its speed and stability. However, these systolic volumes of the 
ventricles do not match those obtained from clinical data, which can reach as low as 
24 cm
3
 and 40 cm
3
 for the left and right ventricles, respectively
92
, but they do exhibit 
the same patterns of volume change through time.
46
  
                                                 
6
 http://www.mathworks.com/matlabcentral/fileexchange/28851-alpha-shapes/content/alphavol.m 
Figure 25: Delaunay 
triangulation of the left ventricle 
to calculate volume 
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Figure 26: Volume change through time of A)left and B)right ventricles with the 
Holzapfel and Ogden model vs. the Pole-Zero and the Mooney-Rivlin models 
 
b) Ejection Fraction 
The ejection fraction (EF) is the percentage of blood ejected from the ventricles 
during contraction. It is a very good indicator of how healthy the heart is, by 
measuring how well it is pumping blood. It is calculated from the formula
93
; 
 
      
       
   
    (3.7) 
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where EDV is the end diastolic volume and ESV is the end systolic volume.  The 
values of the EFs predicted by the Holzapfel and Ogden, the Pole-Zero, and the 
Mooney-Rivlin models are shown in Table 2.  
Table 2: Ejection Fraction values for Holzapfel and Ogden vs. Pole-Zero and 
Mooney-Rivlin models 
Holzapfel and Ogden Pole-Zero Mooney-Rivlin 
LV RV LV RV LV RV 
28.2% 21.8% 18.7% 12.2% 16.8% 11.6% 
 
As expected from the volume change curves, the Holzapfel and Ogden model 
exhibits a larger EF than the Pole-Zero and Mooney-Rivlin models due to the larger 
change in volume. The values are still considerably far from clinical data
94
, but are 
consistent with various computational model results in literature
51
, and should thus be 
sufficient for our purpose of detecting the change in the heart’s performance under 
drug influence. In fact, this newly developed model provides a considerable 
improvement to the ones on Chaste. 
 
c) Left Ventricle Twist 
The helical structure of the fiber distribution in the ventricles induces torsion  
in the cardiac muscles during contraction, and plays a crucial role in ventricular blood 
filling and ejection.
46
 As shown in Figure 27, to measure the twist angle in the LV, we 
define an axial vector, which extended from a fixed point at the apex to the middle of 
the cavity at the base, whose orientation we follow in the initial and the contracted 
meshes. A second (radial) vector was extended from the axial vector, standing at the 
base, in the middle of the LV cavity, to a chosen point on the LV wall. We also follow 
the motion of this radial vector in the initial and contracted meshes. Note that 
measuring the angle between the initial and  deformed radial vectors is not suitable, 
since their orthogonality to the axial vector is not guaranteed, particularly after 
contraction. Hence, a third (normal) vector, orthogonal to both the axial and the radial 
vectors in each of the meshes, is obtained from the cross product of the axial and 
radial vectors.  The angle between these normal vectors in the intial and deformed 
meshes is thus calculated to indicate the twist angle of the LV.   
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Figure 27: A) Undeformed mesh with an axial vector (blue) through the LV and a 
radial vector(yellow) connecting it to the LV wall B) Deformed mesh with an 
axial vector (red) through the LV and a radial vector(green) connecting it to the 
LV wall 
 
Unlike the Mooney-Rivlin model, the resulting twist angle for both transverse 
isotropic material models is in very good agreement with the range of experimental 
measures in literature.
95,96
 The changing twist angle over time is plotted in Figure 28. 
The Holzapfel and Ogden model predicts a maximum twist angle of 15.3 degrees 80 
ms into the simulation while the Pole-Zero model predicts a lower maximum twist 
angle of 12 degrees at 90 ms and the Mooney-Rivlin model predicts a maximum twist 
angle of 5.2 degrees at 150 ms. The low twisting effect of the Mooney-Rivlin model is 
a clear consequence of the lack of fiber and sheet orientation definitions which 
indicates their importance in recreating the LV torsion of the contracting heart.  
More interesting, is that the trend the Holzapfel and Ogden model predicts for 
LV twist angle is more similar to clinical data than the other two models
46
, which 
confirms it is an important improvement of the models in Chaste.   
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Figure 28: Left Ventricle rotation angle change over time of the Holzapfel and 
Ogden model vs. the Pole-Zero and the Mooney-Rivlin models 
 
d) Longitudinal and Radial Strains 
The longitudinal and radial strains 
are the main indicators of change in 
dimensions. The longitudinal strain is 
measured through the septum as shown in 
Figure 29 to indicate longitudinal 
shortening during contraction. Two radial 
strains are also measured for each 
ventricle, one in the lengthening direction 
(long) and the other in the shortening 
direction (short) as shown in Figure 30.  
The radial strains measured in this 
study cannot compare favorably to clinical measurements since the deformation at the 
base of the ventricles is actually limited by its attachment to the atria. However, the 
measurements are here used to evaluate the change in model dimensions for the 
different material models, and under the influence of drugs. 
Figure 29: Longitudinal axis from apex 
to base in the undeformed (pink) and 
deformed meshes (orange) 
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Figure 30: Radial lines indicating their position in the undeformed mesh (left) 
and in the deformed mesh (right) 
 
 The plot of the longitudinal strain through time is shown in Figure 31. The 
results further support that the Holzapfel and Ogden model is able to produce more 
longitudinal shortening, of 12.8%, and exhibit stronger contractile effects than the 
Pole-Zero, whose maximum shortening is 11.7% and the Mooney-Rivlin with 
maximum shortening of 9.1%. 
 
 
Figure 31: Longitudinal strain plot for the Holzapfel and Ogden model vs. the 
Pole-Zero and the Mooney-Rivlin models 
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 From the basal view, the ventricles appear to be squeezed in one direction and 
stretched in the other, so the radial strain is measured in both directions for each 
ventricle. Figure 32 of the LV long side deformation indicates that the anisotropic 
models exhibit the same maximum stretch, but different patterns of deformation. 
However, for the short side, plotted in Figure 33, the Holzapfel and Ogden model 
causes the LV to record larger contraction than the Pole-Zero model. The Mooney-
Rivlin plots indicate that the model does not reach the levels of stretching and 
squeezing of the other two models due to the stiffness of the model resulting from the 
lack of fiber and sheet directions. 
 
Figure 32: Left Ventricle strain in the long direction for the Holzapfel and Ogden 
model vs. the Pole-Zero and Mooney-Rivlin models 
 
Figure 33: Left Ventricle strain in the short direction for the Holzapfel and 
Ogden model vs. the Pole-Zero and Mooney-Rivlin models 
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 With the regards to the radial strains of the RV, for the long side, all three 
models appear to exhibit a similar stretch pattern. However, the Pole-Zero model 
seems to be somewhat delayed and the Mooney-Rivlin model gives significantly less 
stretching. As for the short side, they again predict similar strain patterns, but the 
Holzapfel and Ogden model again records a higher shortening percentage than both 
the Pole-Zero and the Mooney-Rivlin models. The percentages of stretching and 
shortening are recorded in Table  3. 
 
Figure 34: Right Ventricle strain in the long direction for the Holzapfel and 
Ogden model vs. the Pole-Zero and the Mooney-Rivlin models 
 
 
Figure 35: Right Ventricle strain in the short direction for the Holzapfel and 
Ogden model vs. the Pole-Zero and the Mooney-Rivlin models 
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Table 3: Radial stretching and shortening of the Holzapfel and Ogden model and 
the Pole-Zero model 
Holzapfel and Ogden Pole-Zero Mooney-Rivlin 
LV RV LV RV LV RV 
Long Short Long Short Long Short Long Short Long Short Long Short 
24% 30% 19% 42% 24% 26% 19% 32% 14% 15% 14% 18% 
 
 In summary, the results comparing between the two mechanical models 
validate the Holzapfel and Ogden model we developed on Chaste for this study, and 
in fact the various biomarkers we studied provide sufficient evidence that it gives 
superior results in terms of predicting cardiac functionality. The results also validate 
the need for fiber orientation definition especially for the modeling of the LV twisting 
and the longitudinal shortening. 
 Therefore, the Holzapfel and Ogden model was selected for the investigation 
of the effect of nanodrug influence on cardiac mechanics, whose results are reported 
next. 
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C) Effects of Sodium channel blockage 
The sodium channel activation is responsible for the depolarization of cardiac 
myocytes.
97
 Sodium channel blocks are known to cause activation time delays 
resulting from the decrease in conduction velocity through the cardiac tissue.
26
 This 
blockage can be caused by drugs of the type Class I antiarrhythmics, which 
specifically target the sodium channels, or even by non-cardiovascular drugs such as 
antipsychotics and anticonvulsants.
97
 The simulation was carried out using the 
Holzapfel and Ogden model under the same conditions of the Holzapfel and Ogden 
control simulation with an IC50 dose of a sodium channel blocker. 
i) Electrophysiology 
Figure 36A compares the average activation time of the simulation under the 
influence of a sodium channel blocker with the control and shows an average delay of 
about 9 ms. The conduction velocity was also plotted in Figure 36B showing the 
sodium channel block causing a decrease in conduction velocity of the action 
potential in the ventricles. Figure 37 compares the conduction velocities of the control 
and sodium channel blocked simulations. It shows how far along the ventricles the 
electrical wave has spread at t = 45ms showing the one under drug influence to be 
clearly falling behind. This activation delay and reduced conduction velocity are 
consistant with findings in literature.
26
 
 
Figure 36: The A) activation time and B) conduction velocity of action potential 
through the ventricles for control (blue) and for IC50 dose of a sodium channel 
blocker (red) 
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Figure 38 plots the simulated effect of the sodium channel blocker on pseudo-
ECG against the control. Results show a clear prolongation in the QRS complex due 
to the decreased rate of depolarization and, even though the blockage does not affect 
repolarization, the T-wave experiences a shift forward as a result of the delayed 
activation. The alterations in the QT interval match those reported in literature.
43
 
 
Figure 38: Pseudo-ECG QT interval for control (blue) and for IC50 dose of a 
sodium channel blocker (red) 
 
This consequence of the conduction delay during activation on the 
repolarization is also clear in the AP plot in Figure 39. The changes in the AP curve 
are also consistant with the literature.
23,26
 It exhibits a decrease in maximum voltage 
amplitude and a deflection in the activation-repolarization cycle which results in the 
prolongation of the action potential duration. Figure 40 shows a difference in 
Figure 37: Electrical wave propagation along the ventricular mesh for A) control and B) 
sodium channel blockage 
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repolarization times between the control and the influence of sodium channel block of 
about 9 ms, which is the same difference between the activation times confirming that 
there is no additional effect on the repolarization by the sodium channel block. 
 
Figure 39: Action potential for control (blue) and for IC50 dose of a sodium 
channel blocker (red) 
 
Activation time maps for the 
ventricular model in Figure 41 show the 
effect of the sodium  channel blocker on 
the tissue activation time.  The color 
gradient in Figure 41A shows the 
maximum time for tissue activation under 
normal conditions is 77 ms while in Figure 
41B under sodium channel blocker 
influence, the same tissue activation time 
reaches 100 ms. Figure 42 compares the 
repolarization time maps highlighting the 
slight delay in the drug influences 
simulation. The activation maps produced 
appear to have similar patterns to those found in literature.
26
 
Figure 40: Repolarization time for 
control (blue) and for IC50 dose of a 
sodium channel blocker (red) 
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Figure 41: Activation time maps of the ventricular meshes A) under control 
conditions and B) under the influence of sodium channel blocker 
 
 
Figure 42: Repolarization time maps of the ventricular meshes A) under control 
conditions and B) under the influence of sodium channel blocker 
 
It is thus established that simulation results are consistent with experimental 
results
21
 and computational model results
26,43
 in literature regarding the effect of 
sodium channel blockers on the reduced rate of depolarization and the decreased 
action potential conduction velocity. 
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ii) Tissue Deformation  
  As previously discussed, so far 
in literature the effect of drugs has only 
been studied on the electrophysiology 
of the heart. Studying the mechanical 
results will give an answer to how 
much these electrical changes affect the 
mechanical pumping of the heart. 
The mechanical results of the 
coupled simulation under the influence 
of an IC50 dose of a sodium channel nanodrug were compared to the control run under 
normal conditions using the same Holzapfel and Ogden material model. Figure 43 
shows the ventricular contraction of the two simulations superimposed with the 
control as the solid pink mesh and the nanodrug influenced as the translucent green. 
They appear to be slightly out of synch, but the data needs to be quantified to 
understand the extent of the nanodrug effect on the heart function . 
 The effective deviatoric strain distribution maps of the nanodrug influenced 
model are compared against the control in Figure 44. However, no observable 
difference can be noted between the two strain distributions.  
The effective deviatoric stress distribution maps are also compared in Figure 
45. There does appear to be a slight difference between the 2 distributions. In Figure 
45A, stresses seem to rise at the endocardium of the LV at the base in the control 
simulation, while they are only just starting to appear in the drug influenced model. In 
45B, the stresses rise in the drug influenced model as well, but they appear to be 
behind the control. At the end of the simulation, in Figure 45D, the stresses in the 
drug influenced model seem to be falling at a lower rate than the control model. So 
far, these findings are consistent with what is known about sodium channel blocking 
causing a delay in the cardiac cycle.
18,26
 
The mechanical biomarkers are calculated next for the drug influenced model 
and compared to the control to quantify the extent of the effect of the sodium channel 
blockage on the cardiac function. 
Figure 43: Ventricular contraction of the 
control (solid pink) vs. Na+ blocked 
model (translucent green) 
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Figure 44: Strain distribution maps of the control on the left and under Na
+ 
channel blocking on the right at times A) 50 ms, B) 150 ms, C) 250 ms, D) 350 ms 
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Figure 45: Stress distribution maps of the control on the left and under Na
+ 
channel blocking on the right at times A) 100 ms, B) 150 ms, C) 200 ms, D) 350 
ms 
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a) Ventricular Volume 
The volumes of the left and right ventricles was calculated for the drug 
influenced model and plotted against the control. The results are shown in Figure 46. 
Both models exhibit similar trends and reach the same minimum ventricular volumes, 
but the drug-induced model seems to be lagging behind the control in both the LV and 
the RV and this lag not only affected the muscle contraction, but the volume 
restoration is falling behind as well. These results indicate that the ventricular 
performance has been shifted as a result of the electrophysiology delay.  
 
Figure 46: Volume change through time of A) left and B) right ventricles under 
normal conditions and under IC50 dose of Na
+
 channel blocker 
 
59 
 
b) Ejection Fraction 
The EFs of  the drug induced model were calculated and compared to the 
control. The results are recorded in Table 4. The LV EF appears to be unaffected while 
the RV, interestingly, seems to have exhibited an increase in the ejection fraction. As 
far as we know, these results are new and there are no reports to compare them to. 
Table 4: Ejection Fraction values for the control vs. the Na
+
 channel blocked 
model 
Control Sodium Channel Blocker 
LV RV LV RV 
28.2% 21.8% 28.2% 22.5% 
 
c) Left Ventricle Twist 
The twisting motion of the LV is crucial in the cardiac functionality and risky 
if compromised. Figure 47 plots the LV twist angle of the drug induced model against 
the control. As expected, the rate of angle twist decreases as a consequence of the 
sodium channel block delay. This checks out with the literature.
19
 However, the 
maximum twist angle reached by the LV is higher in the drug induced model reaching 
almost 17 degrees. This result is also new and unpredicted and the cause of which 
would make for an interesting study. 
 
Figure 47: Left Ventricle rotation angle change over time under normal 
conditions and under IC50 dose of Na
+
 channel blocker 
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d) Longitudinal and Radial Strains 
As shown in Figure 48, the longitudinal strain measures of the drug influenced 
model exhibit similar trends to the control, but at a lower rate. The same longitudinal 
axis shortening during contraction is achieved by both models, but, as predicted by 
the electrophysiology, the drug influenced model was delayed.
18,19
 
 
Figure 48: Longitudinal strain under normal conditions and under IC50 dose of 
Na+ channel blocker 
The same delay is experienced in the radial strains as well. However, in both 
ventricle, except for the stretching in the RV long direction, which is similar to the 
control, there appear to be a higher percentage of stretching and shortening in the drug 
induced model. The exact percentages are recorded in Table 5 and the radial strain 
plots of the LV and RV are shown in Figures 49, 50, 51 and 52. This increased 
mechanical performance is an unexpected finding and more research is needed to 
understand its cause and subsequent effect. 
Table 5: Radial stretching and shortening of the control and Na+ channel 
blocked model 
Control Sodium Channel Block 
LV RV LV RV 
Long Short Long Short Long Short Long Short 
24%, 30% 19% 42% 25.8% 32.2% 19% 45.8% 
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Figure 49: Left Ventricle strain in the long direction for control and Na
+
channel 
blocked model 
 
 
Figure 50: Left Ventricle strain in the short direction for control and Na+channel 
blocked model 
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Figure 51: Right Ventricle strain in the long direction for control and 
Na+channel blocked model 
 
 
Figure 52: Right Ventricle strain in the short direction for control and 
Na+channel blocked model 
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D) Simulation of the effects of Potassium channel blockage 
In simulating the effect of 
potassium channel blockage on the 
function of the heart, the effect of ultra-
small gold nanoparticles of 1.4 nm 
diameter (Au1.4MS) that are frequently 
used as drug carriers were chosen as an 
example drug to investigate. With an 
IC50 value of 48 μM
17
 the potassium 
channel blockage of 100 μM 
concentration of the drug, using the 
formula in equation (2.1) causes a 
blockage of 68%. A simulation was 
carried out under the same control 
conditions with 100 μM concentration 
of Au1.4MS as the potassium channel blocker. 
i) Electrophysiology 
Figure 53 shows the difference in repolarization time of about 30 ms between 
the control simulation and AuNP-influenced simulation. A side by side comparison of 
the 2 simulations at time 300 ms during repolarisation shows the control simulation 
ahead of the drug influenced once is shown in Figure 54. These results are a good 
match to reports in literature.
26
 
 
Figure 54: Repolarization of the ventricular mesh tissue of A) control and B) 
AuNP-influenced simulations 
Figure 53: Average repolarization time 
of the ventricles for control (blue) and 
for Au1.4MS influence (red) 
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The pseudo-ECG of the potassium channel blocking simulation in Figure 55 
does not show difference from the control during the depolarization in the QRS 
complex. The change can be observed in the increase in the QT interval and the lower 
T-wave amplitude due to decreased dispersion during repolarization similar to 
changes reported in literature.
44,98 
 
Figure 55: Pseudo-ECG QT interval for control (blue) and for Au1.4MS 
influence (red) 
 
In Figure 56, the AP plot comparing the results of the control and potassium 
channel blocker, shows the activation in both cases as almost exactly the same. The 
deviation can be seen during the repolarization phase of the action potential as 
potassium channel blockage leads to delayed repolarization and increase in action 
potential duration. The results appear to be consistent with reports in literature.
44,98
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Figure 56: Action potential for control (blue) and for Au1.4MS influence (red) 
 
Repolarization time maps for the ventricular model in Figure 57 show the 
effect of the potassium channel blocker on the tissue repolarization time.  The color 
gradient in Figure 57A shows the maximum time for tissue repolarization under 
normal conditions is 391 ms while in Figure 57B under nanodrug influence, the same 
tissue repolarization time reaches 397 ms. The simulation results are as such 
consistent with findings in literature regarding the effect of potassium channel 
blockers on the action potential duration prolongation due to the decreased rate of 
ventricular tissue repolarization.
26
 
 
Figure 57: Repolarization time maps of the ventricular mesh under A) normal 
conditions and B) the influence of potassium channel blocker 
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ii) Tissue Deformation 
 Figure 58 shows the ventricular 
mesh at the end of the simulation near the 
end of the cardiac cycle in the control and 
the AuNP-influenced models. From the 
electrophysiological results, potassium 
channel blockers are known to cause 
repolarization delay.
44
 Therefore, 
differences between the behavior of the 
control and the AuNP-induced model 
should begin to appear near the end of 
the simulation during ventricular 
relaxation. There does not appears to be 
any visual difference between them the 2 
models in Figure 58.  
 The effective deviatoric strain and the effective deviatoric stress maps of the 
AuNP-induced model are shown in Figures 59 and 60, respectively, in comparison 
with the control model. The stress and strain color distributions do not show any 
difference between the two models either. According to electrophysiological 
findings,
44
 the results are expected to remain identical for about 250 ms after which 
change is expected, but so far doesn’t appear. The other biomarkers are needed to 
shed more light on the AuNP-influenced mechanical behavior of the heart. 
 
 
 
 
 
Figure 58: Ventricular contraction 
of the control (solid pink) vs. K+ 
channel blocked model (translucent 
green) 
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Figure 59: Strain distribution maps of the control on the left and under K
+
 
channel blocking on the right at times A) 50 ms, B) 150 ms, C) 250 ms, D) 350 ms 
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Figure 60: Stress distribution maps of the control on the left and under K
+
 
channel blocking on the right at times A) 50 ms, B) 150 ms, C) 250 ms, D) 350 ms 
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a) Ventricular Volume 
The left and right ventricular volumes were calculated at each time step and 
compared to the control volume measurements. The plots are shown in Figure 61. The 
volume change in the LV is exactly the same in both the control and the AuNP-
induced model. As for the RV volume, there appears to be an extremely slight change  
between the 2 models at the very last simulation time step. Other than that, the 
volume change is identical. The ventricular volume restoration was expected to slow 
down as the repolarization in the AP slows down
26
, but that effect did not appear. 
 
Figure 61: Volume change through time of A) left and B) right ventricles under 
normal conditions and under K
+
 channel blocker 
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b) Ejection Fraction 
The EF is not a suitable biomarker for potassium channel blockage as it does 
not affect the activation
26
 and therefore does not affect systole. Since there is no 
volume change between the 2 models, the EF of the AuNP-induced model is identical 
to the control. The values are shown in Table 6. 
Table 6: Ejection Fraction values for the control vs. the K
+
 channel blocked 
model 
Control Potassium Channel Blocker 
LV RV LV RV 
28.2% 21.8% 28.2% 21.8% 
 
c) Left Ventricle Twist 
Again, the twist angles of the drug-induced model are the same as the control 
which is as expected since the twist occurs near the beginning of the cycle where the 
potassium channel block shows no effect on  the electrophysiology.
26,44
 However, 
between the times 300 ms and 350 ms, a small change starts to appear between the 2 
models, as seen in Figure 62. 
 
Figure 62: Left Ventricle rotation angle change over time under normal 
conditions and under K
+
 channel blocker 
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d) Longitudinal and Radial Strains 
Figure 63 plots the longitudinal strain of the drug induced model against the 
control. The LV and RV radial strains are plotted as well in Figures 64, 65, 66 and 67. 
The strains shows the same behavior of the other biomarkers where the results are 
identical to the control. Again this is unexpected. More visible differences were 
expected to appear near the end of the cycle such as a slower rate of recovery. 
 
Figure 63: Longitudinal strain under normal conditions and under K
+
 channel 
blocker 
 
Figure 64: Left Ventricle strain in the long direction for control and K
+ 
channel 
blocked model 
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Figure 65: Left Ventricle strain in the short direction for control and K
+ 
channel 
blocked model 
 
 
Figure 66: Right Ventricle strain in the long direction for control and K
+ 
channel 
blocked model 
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Figure 67: Right Ventricle strain in the short direction for control and K
+ 
channel blocked model 
 
 Potassium channel blockers are known to affect the final (repolarization) 
phase of the cardiac cycle. So its behavior being identical to the control is expected in 
the first half or two thirds of the cycle. As expected, there was no change in the EF or 
the maximum LV twist angle as these two biomarkers are systole quantifying 
biomarkers. The differences were expected to be seen in the restoration curves of the 
volume and strain plots. The differences were expected to appear at around the same 
time they appear in the electrophysiology which is at 250 ms. That did not happen and 
only very slight changes appeared in some cases at the very end of the simulation. The 
most likely reason it is late in showing compared to electrophysiology is that the 
mechanical deformation is slow to respond to electrical excitation. The fact that only 
350 ms of the cycle are available in this study is a shortcoming since the effect may 
appear in the last 50 ms and pass over into the next cycle.  
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E) Simulation of the effects of Calcium channel blockage 
 
Calcium dynamics form the link between electrical activation and mechanical 
contraction
63
 since the generation of the active tension depends on intracellular 
calcium concentration as previously mentioned.
60
 The L-type calcium channel is a 
pathway found in all cardiac cell membranes and is the principle pathway of calcium 
into the cell.
2
 The blockage of L-type calcium channel has been known to cause 
reduction in the T-wave amplitude and shortening in the QT interval caused by the 
reduction of the action potential duration.
42
 Drugs that cause calcium channel 
blocking have many clinical applications such as reducing blood pressure and altering 
heart rate.
42
 A simulation was carried out under the influence of the IC50 dose of a 
calcium channel blocker using the same control conditions and the results are shown 
below. 
i) Electrophysiology  
Figure 68 shows the 
difference in average 
repolarization times between the 
control  and under the influence 
of a calcium channel blocker. The 
plot shows the simulation with 
the calcium channel blocker 
repolarizing about 50 ms ahead 
of the control simulation.  
Figure 69 shows a side by 
side comparison of the electrical 
potential of the two simulations at 
time 300 ms during repolarization. 
The images show the repolarization of the drug-influenced simulation to be clearly 
ahead of the control. These results are consistent with findings in literature.
42
 
Figure 68: Average repolarization time of the 
ventricles for control (blue) and for IC50 dose 
of a calcium channel blocker (red) 
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Figure 69: Repolarization of the ventricular mesh tissue at time 300 ms of A) 
control and B) calcium channel blockage 
 
 The effect of blocking L-type calcium channel on the pseudo-ECG is plotted 
against the control in Figure 70. The drug barely affects the QRS complex with only a 
very small decrease its amplitude. The T-wave, however, experiences a significant 
shift backwards leading to shortening of the QT interval. There is also a slight 
decrease in the T-wave amplitude. These alterations in the QT interval match those 
reported in literature.
42
 
 
Figure 70: Pseudo-ECG QT interval for control (blue) and for IC50 dose of a 
calcium channel blocker (red) 
 
  
76 
 
The action potential plot comparing the control simulation with the simulation 
under the influence of a calcium channel blocker is shown in Figure 71. The 
activation of both appear to be almost the same except for a slight reduction in 
amplitude of the drug-influenced simulation. A more significant difference appears in  
the plateau and repolarization phases. There is a reduction in the voltage at the plateau 
phase and early repolarization for the drug-influenced simulation which agree with 
reports in literature.
99
 
 
Figure 71: Action potential for control (blue) and for IC50 dose of a calcium 
channel blocker (red) 
 
 Repolarization time maps for the ventricular model shown in Figure 72 show 
the effect of L-type calcium channel blocking on the tissue repolarization time. The 
color gradient in Figure 72A shows the maximum time for tissue repolarization under 
normal conditions is 368 ms while in Figure 72B under drug influence, the same 
tissue repolarization time reaches only 318 ms.  
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Figure 72: Repolarization time maps of the ventricular mesh under A) normal 
conditions and B) the influence of calcium channel blocker 
 
All the electrophysiological simulation results are as such consistent with 
findings in literature regarding the effect of L-type calcium channel blockers on the 
action potential duration shortening due to early repolarization.
42,99
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iii) Tissue Deformation  
The electrophysiological simulations 
indicate that the calcium channel blocked 
model should repolarize and reach the end of 
the cardiac cycle 50 ms before the control. 
This means that the nanodrug induced model 
should be relaxing much faster than the 
control. That, however, does not seem to be 
the case in Figure 73 which shows the 
superimposed ventricular models of both the 
control and the calcium channel blocked 
model. There doesn’t appear to be any visible difference between the relaxation of the 
two models. 
 The comparison between the effective deviatoric strain and the effective 
deviatoric stress maps of the L-type calcium channel blocked model and the control 
are shown in Figures 74 and 75, respectively. The stress and strain color distributions 
do not show differences between the two models either. According to 
electrophysiological findings,
42
 differences are expected to appear in the results, at 
least during diastole, but so far there are none. Further mechanical biomarkers are 
needed to shed light on the calcium channel blocking nanodrugs’ influence on 
mechanical behavior of the heart. 
 
 
 
Figure 73: Ventricular models of the 
control (solid pink) vs. Ca
2+
 channel 
blocked model (translucent green) 
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Figure 74: Strain distribution maps of the control on the left and under Ca
2+
 
channel blocking on the right at times A) 50 ms, B) 150 ms, C) 250 ms, D) 350 ms 
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Figure 75: Stress distribution maps of the control on the left and under Ca
2+
 
channel blocking on the right at times A) 50 ms, B) 150 ms, C) 250 ms, D) 350 ms 
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a)  Ventricular Volume 
The left and right ventricular volumes were calculated at each time step and 
compared to the control volume measurements with the results plotted in Figure 76. 
The volume change in the LV and the RV are similar in both the control and the 
nanodrug-induced model. Reports in literature
42,99
 and the electrophysiological results 
of the simulation support the expectation that the ventricular volume for the calcium 
channel blocked model was to be restored faster than the control. The direct link 
between the calcium concentration and the ventricular mechanical response
60
 also 
supports the claim that the blocking the calcium channel would have a significant 
effect on the volume change. However, neither of these expectations occurred in the 
volume change of both models. 
 
Figure 76: Volume change through time of A) left and B) right ventricles under 
normal conditions and under Ca
2+
 channel blocker 
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b) Ejection Fraction 
Since calcium channel blocking with an IC50 dose did not affect ventricular 
contraction in our simulation of a single cardiac cycle,
60
 no difference was predicted 
between the control and the nanodrug-induced EFs. There appears to be a very slight 
increase in the EF of the RV in the nanodrug-influenced model; however, we deem it 
too small to have significance in the simulated cycle. The values are given in Table 7. 
Table 7: Ejection Fraction values for the control vs. the Ca
2+
 channel blocked 
model 
Control Calcium Channel Blocker 
LV RV LV RV 
28.2% 21.8% 28.2% 21.9% 
 
c) Left Ventricle Twist 
As shown in Figure 77, the calcium channel block does not appear to have any 
significant effect on the LV twist angle value. Neither was the LV twisting restored 
faster in the model under the nanodrug influence, nor was the twisting strength 
affected by the change in the calcium concentration. 
 
Figure 77: Left Ventricle rotation angle change over time under normal 
conditions and under Ca
2+
 channel blocker 
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d) Longitudinal and Radial Strains 
The longitudinal strain of the calcium channel blocked model against the 
control is plotted in Figure 78. The LV and RV radial strains are plotted as well in 
Figures 79, 80, 81 and 82. The behavior of the strains is similar to the behavior of the 
other biomarkers with the results similar to the control. Contrary to the reported 
results, visible differences were expected to appear during the cycle due to the change 
in the calcium concentration and the strain values were expected to be restored 
faster.
42, 60
 
 
Figure 78: Longitudinal strain under normal conditions and under Ca
2+
 channel 
blocker 
 
Figure 79: Left Ventricle strain in the long direction for control and Ca
2+ 
channel 
blocked model 
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Figure 80: Left Ventricle strain in the short direction for control and Ca
2+
 
channel blocked model 
 
Figure 81: Right Ventricle strain in the long direction for control and Ca
2+
 
channel blocked model 
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Figure 82: Right Ventricle strain in the short direction for control and Ca
2+
 
channel blocked model 
 
L-type calcium channel blockers are known in literature to reduce the QT-
interval and the action potential duration due to early repolarization.
42,99
 The calcium 
dynamics are also known to be the direct link between the electrophysiology and the 
mechanical contractile behavior of the cardiac tissue.
60
 Therefore, our expectation by 
applying an IC50 value of a calcium channel blocker was to predict a disturbance in 
the mechanics of the whole cycle compared to the control. That, however, was not the 
case as seen in the results of the tissue deformation biomarkers. The results were all 
similar to the control. The IC50 value of a calcium channel blocker was enough to 
cause electrophysiological changes; however, it could be that the mechanics is not 
sensitive enough to detect these changes, so that a greater channel inhibition needs to 
be tested for mechanical disturbances to appear. It is also thought that one cardiac 
cycle is not sufficient to affect the deformation abnormalities, so that modeling more 
than one cycle could be needed to access the effect of calcium channel blockage on 
the mechanical behavior. Thus, our predictions on calcium blockage will need to be 
elaborated in future work. 
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4) Conclusion 
The objectives of this study were to model accurately a single ventricular 
contraction-relaxation cycle and monitor the effect induced by nanodrugs on LV and 
RV electro-mechano-physiology. The objectives of this study were thus achieved. The 
nanodrugs causing sodium channel blockage were found to produce the expected 
delays, and predicted additionally other effects on LV twisting and ventricular strain. 
The nanodrugs causing potassium and calcium channel blockage showed that the 
mechanics does not respond as quickly to the electrophysiology as does the 
electrophysiology to ionic changes. Nonetheless, it is possible for small deviations 
from the normal to accumulate over multiple cardiac cycles, and lead to adverse 
consequences on cardiac health in the long term. As such, multi-cycle investigations 
of K
+
 and Ca
2+
 effects on cardiac electro-mechanics are recommended for future 
work. 
Chaste was chosen as the software to build our model on, as it offers an open 
source multiphysics framework to build the coupled (drug-electro-mechano-
physiological) system.  
Two material laws for modeling passive material stress were already in place 
on Chaste; however, new reports in literature suggested that the orthotropic Holzapfel 
and Ogden material law was better suited than the isotropic (Mooney-Rivlin) or the 
transversely isotropic hyperelastic model (Pole-Zero) available in Chaste. The 
Holzapfel and Odgen material law was thus developed for implicit finite element 
implementation, incorporated on Chaste, and used to solve the coupled multiphysics 
model. To check the validity of the material law, it was compared to the transverse 
isotropic Pole-Zero law. To validate the importance of fiber orientation definition in 
mechanical modeling, the Holzapfel and Odgen model was also compared to the 
isotropic Mooney-Rivlin model. 
 All three models solved 90% of the target cardiac cycle, before meeting mesh 
instabilities. The results showed not only that the Holzapfel and Ogden model was 
less stiff than both the Pole-Zero model and the Mooney-Rivlin model, but that even 
when using the material law as transversely isotropic (confining it to four parameters 
only, and not using its full orthotropic capability), it showed better mechanical 
performance in terms of ventricular volume reduction, ejection fraction, left 
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ventricular twisting, and longitudinal shortening. These are all key mechanical 
biomarkers where the Holzapfel and Ogden model outperforms its competitors pre-
programmed on Chaste. 
 Encouraged by the mechanical predictions of the Holzapfel and Ogden model, 
three nanodrug effects were then investigated in the coupled multiphysics framework, 
in the form of the IC50 value of a sodium channel blocker (such as silver 
nanoparticles), a 100 μM dose of ultrasmall gold nanoparticle drug carriers and the 
IC50 value of a calcium channel blocker (such as ZnO nanoparticles). The 
electrophysiological predictions were found to be consistent with the information 
published in literature. For the mechanics, the delay in the electrical activation caused 
by the sodium channel blocker was translated into a delay in all the mechanical 
biomarkers of the ventricles, as expected. Further interesting predictions were made, 
which require further study; they are the increased LV twist angle and the increased 
stretching and shortening of the ventricles in the radial directions as a result of sodium 
channel blockage.  
For the potassium channel blocking effect the results turned out, predictably, 
the same as for the control, since the electrical activation and hence the contraction 
are not affected by potassium channel blockage. Unfortunately, modeling only 90% of 
the cycle was thus not enough to reveal how ventricular relaxation would be affected, 
since the effects were only starting to appear as the simulation terminated. 
As for the calcium channel blocker, the IC50 value was enough to cause 
electrophysiological changes from the control, however, these changes were not 
translated to the tissue mechanics. It might be that the mechanics are not sensitive 
enough to detect these changes, so a larger channel inhibition needs to be tested for 
mechanical disturbances to appear, or one cardiac cycle is just not sufficient to affect 
the deformation abnormalities and modeling more cycles will be required to access 
the effect of calcium channel blockage on the mechanical behavior. 
 For the future work of this study more information is needed to understand the 
unexpected mechanical behavior of the sodium channel blocked model and the 
calcium channel blocked model and to acquire more conclusive results about the 
potassium channel blocked model. The first step would be to fix the mesh stability of 
the models on Chaste, e.g. using compressible models with a large bulk modulus to 
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mimic incompressible behavior less restrictively, to enable the completion of the first 
cardiac cycle and to open the possibility of modeling more than one cycle.  
Another issue that might be affecting the sensitivity of the model to the 
nanodrug effects is that the mechanical response is not fed back to the 
electrophysiology. This feedback effect was not accounted for in this work since, on 
Chaste, it is very computationally expensive to apply on big meshes such as the one 
used here. Nonetheless, this two-way coupling is crucial and needs to be tested since 
even small changes in the mechanics could amplify electrical changes which in turn 
would amplify changes in the mechanics. 
Improvement to EF can be made in the LV and RV simulation if we revise the 
boundary conditions. Fixing the apex and leaving the base free is the opposite of the 
natural order of things. At the moment these boundary conditions are the most stable. 
It is a good compromise since the ventricles are still able to contract and twist, 
however, the lack of atria in the model leave the base completely free to spread as the 
muscles contract downwards as shown in Figure 83 and as evidenced from the radial 
strain results.  
 
Figure 83: Longitudinal slice through the ventricles A) in diastole and B) in 
systole 
 
The trick lies in finding boundary conditions that simulate the effect of atrial 
attachment to the base without increasing its stiffness. Sliding wall boundary 
conditions are currently being tested where the boundary nodes can be fixed in one or 
two directions and left to slide freely in the third, but it is facing graver stability 
issues. Since, Dirichlet boundary conditions are not the best option for biological soft 
tissue, Robin-like boundary conditions, where a spring-like and viscous effect is 
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applied at the desired surface, are also being investigated. Improving the boundary 
conditions is expected to primarily achieve significant improvements to the 
mechanical performance of the model in terms of ventricular volume reduction and 
ejection fraction, and further contribute to model stability to simulate multiple cardiac 
cycles. 
 Another problem that might be compromising the stability, is the selected 
mechanics solver time step. The problem was set to solve the mechanics every 10 ms 
as solving the mechanics problem for such a large mesh is computationally very 
expensive. The idea provided a significant speed-up, but seemed to experience 
difficulty near the end of the simulation, which eventually crashed. If the muscles are 
relaxing too quickly during repolarization, the mechanical changes in each time step 
might be too great for such a spaced out time-stepping scheme.  
 From the perspective of drugs, combining nanodrug effects is an important 
phenomenon to look into since some nanocomposites could contain more than one ion 
channel inhibiting component or even a single nanoparticle such as CuO mentioned in 
the introduction could be associated with both sodium and potassium channel 
blocking.  
 With the quick advances taking place in the field of nanomedicine and the 
excitement of the potential it holds, the side effects need to be considered and 
monitored. Computational models are an inexpensive way of doing that. Therefore, 
the more the data and information that can be obtained from the drug testing models, 
the more accurate and reliable they can become and the more widely used they will 
be. This could significantly reduce the need for animal testing and reduce the time and 
cost it takes to release a much-needed cure for a disease. 
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